Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic leukemia once treatment is initiated

Journal of Clinical Oncology

Volumn 23, Issue 7, 2005, Pages 1514-1521

  Starczynski, Jane ^a   Pepper, Chris ^a   Pratt, Guy ^a   Hooper, Laura ^a   Thomas, Alun ^a   Milligan, Donald ^a   Bentley, Paul ^a   Fegan, Christopher ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; BAX PROTEIN, HUMAN; MCL1 PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HEREDITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENE FREQUENCY; GENETICS; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO ONCOGENE; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BCL-2-ASSOCIATED X PROTEIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; GENES, BCL-2; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 14944346868     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.192     Document Type: Article

References (35)

1. Reed JC: Molecular biology of chronic lymphocytic leukaemia. Semin Oncol 25:11-18, 1998
2. Jurgensmeier JM, Xie Z, Deveraux, et al: Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 95:4997-5002, 1998
3. Zamzami N, Brenner C, Marzo I, et al: Subcellular and submitochondrial mode of action of Bcl-2-like proteins. Oncogene 16:2265-2282, 1998
4. Martinou JC, Green DR: Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63-67, 2001
5. van Loo G, Saelens X, Matthijssens F, et al: Caspases are not localized in mitochondria during life or death. Cell Death Differ 9:1207-1211, 2002
6. Janumayan YM, Sansam CG, Chattopadhyay A, et al: Bcl-x(L)/ Bcl-2 coordinately regulates apoptosis, cell arrest and cell cycle entry. EMBO J 22:5459-5470, 2003
7. Pepper C, Thomas A, Hoy T, et al: Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 107:611-615, 1999
8. Bellosillo B, Villamor N, Lopez-Guillermo A, et al: Spontaneous and drug-induced apoptosis is mediated by confirmational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 100:1810-1816, 2002
9. Kitada S, Andersen J, Akar S, et al: Expression of apoptosis regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood 91:3379-3389, 1998
10. Robertson LE, Plunkett W, McConnell K, et al: Bcl-2 expression in chronic lymphocytic leukaemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456-459, 1996
11. Pepper C, Thomas A, Hoy T, et al: Antisense oligonucleotides complementary to Bax transcripts reduce the susceptibility of B-cell chronic lymphocytic leukaemia cells to apoptosis in a Bcl-2 independent manner. Leuk Lymphoma 43:2003-2009, 2002
12. Pepper C, Hoy T, Thomas A, et al: Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2 expressing subclones. Br J Haematol 104:581-588, 1999
13. Faderl S, Keating MJ, Do KA, et al: Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukaemia (CLL). Leukemia 16:1045-1052, 2002
14. Pepper C, Hoy T, Bentley P: Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 28:355-361, 1998
15. Bannerji R, Kitada S, Flinn IW, et al: Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukaemia: Relationship to in vivo Rituximab resistance. J Clin Oncol 21:1466-1471, 2003
16. Dewson G, Snowden RT, Almond JB, et al: Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukaemia cells. Oncogene 22:2643-2654, 2003
17. Saxena A, Moshynska O, Sankaran K, et al: Association of a novel single nucleotide polymorphism, G(-248)A, in the 5′-UTR of Bax gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer Lett 187:199-205, 2002
18. Binet JL, Augier A, Dighiero G, et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206, 1981
19. Cheson BD, Bennett JM, Grever M, et al: National cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukaemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997
20. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215-1222, 1988
21. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
22. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as a novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
23. Stankovic T, Stewart GS, Fegan C, et al: Ataxia telangiectasia mutated deficient B-cell chronic lymphocytic leukaemia occurs in the pre-germinal centre cells and results in defective damage response and unrepaired chromosome damage. Blood 99:300-309, 2002
24. Horowitz M, Goode L, Jarvik GP: Anticipation in familial chronic lymphocytic leukemia. Am J Hum Genet 59:990-998, 1996
25. Wiernik PH, Ashwin M, Hu X-P, et al: Anticipation in familial chronic lymphocytic leukaemia. Br J Haematol 113:407-414, 2001
26. Rawstron AC, Yuille MR, Fuller J, et al: Inherited predisposition to CLL is detectable as a subclinical monoclonal B-lymphocyte expansion. Blood 100:2289-2291, 2002
27. Parker SL, Tong T, Bolden S, et al: Cancer statistics. CA Cancer J Clin. 47:5-27, 1997
28. Yin C, Knudson CM, Korsmeyer SJ, et al: Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 637-640, 1997
29. Zhang L, Yu J, Park BH, et al: Role of Bax in the apoptotic response to anticancer agents. Science 290:989-992, 2000
30. Knudson CM, Tung KSK, Tourtellotte WG, et al: Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96-99, 1995
31. Pedersen IM, Kitada S, Schimmer A, et al: The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 100:2965-2972, 2002
32. Pepper C, Thomas A, Hoy T, et al: The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukaemia cells in vitro. Blood 101:2454-2460, 2003
33. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of human BAX gene. Cell 80:293-299, 1995
34. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619, 1993
35. Selvakumaran M, Lin H-K, Miyashita T, et al: Immediate early up-regulation of bax expression by p53 but not TGF beta-1: A paradigm for distinct apoptotic pathways. Oncogene 9:1791-1798, 1994